PPT-Switch to DOR-TDF-3TC vs. Continued Baseline Regimen

DRIVE SHIFT Switch to DoravirineTDF3TC versus Continued Baseline Regimen DRIVE SHIFT Design Source Johnson M et al J Acquir Immun Defic Syndr 20198146372 Design Openlabel noninferiority trial in adults with suppressed HIV RNA while taking 2 NRTIs plus anchor drug randomized 21 to immediately switch to fixeddose . David Geffen School of Medicine. at University of California Los Angeles. Antiretrovirals. in the Management of HIV Infection: Case-Based, Panel Discussion. From ES . Daar. , MD, at Los Angeles, Ca: April 22, 2013, IAS-USA. . Doravirine. /Lamivudine/TDF is Non-Inferior to . Efavirenz. /. Emtricitabine. /TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study. Kathleen E Squires. 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; . 3. Hospital La Paz, Madrid, Spain; . 4. Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, . implementation of Dolutegravir. Meireles MV. , Pascom ARP, Perini F, Rick F, Benzaken A. . Ministry of Health of Brazil, Department of STI, AIDS and Viral Hepatitis. Acknowledgements. No. . conflicts of interest. David Geffen School of Medicine. at University of California Los Angeles. Antiretrovirals. in the Management of HIV Infection: Case-Based, Panel Discussion. From ES . Daar. , MD, at Los Angeles, Ca: April 22, 2013, IAS-USA. . Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N =. 127. N =. 123. LPV/. r. bid + 3TC/FTC . qd. Design. Randomisation*. 1: 1. Open-label. Objective. Primary Endpoint :. proportion without treatment failure at W48 . Endpoints. Primary: proportion of patients with HIV RNA ≥ 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if upper margin of the two-sided 95% CI for the difference = 4%, 97.3% power . Secondary: proportion of patients with HIV RNA < 50 c/mL at W48 (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI for the difference = - 8%. 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5. ACTG 5202. EFV versus ATV/r, both with ABC-3TC or TDF-FTC. ACTG 5202: Study Design. Source: . Daar. ES, et al. . Ann Intern Med. 2011;154:445-56. . EFV + ABC-3TC. (n = 465). ATV + RTV + ABC-3TC. (n = 463). DRV/r 800/100 + 3TC 300 QD. N = 126. N = 123. DRV/r + ABC/3TC or TDF/FTC QD. Design. Randomisation*. 1: 1. Open-label. Objective. Non inferiority of DRV/r + 3TC at W48: % HIV RNA < 50 c/mL by intention to treat-exposed, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%, 80% power). SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed . ROCKET-1 Trial. Switch from EFV + ABC-3TC to EFV-TDF-FTC. ROCKET-1: Design. Source: Moyle GJ, et al. . PLoS. One. 2015;10:e0116297.. Immediate switch arm. EFV-TDF-FTC. . (n = 79). Delayed switch arm . Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.